75286 Federal Register / Vol. 88, No. 211 / Thursday, November 2, 2023 / Notices 

Æ KQ 2b. Do outcomes vary by patient/ 

client (as well as parent) or clinical or 

organizational characteristics including the 

nature, extent, and timing of exposure (e.g., 

recent or ongoing vs. prior exposure)? 

PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, AND SETTING) 

PICOTS KQ1 KQ2 

Population ............................ Adults 18 years and older, regardless of trauma exposure.Youth <18 years, regardless of trauma exposure. 

1b. Patient/client and clinical characteristics including 

type, time since, and duration of trauma exposure; 

gender; race/ethnicity; age; clinical condition; or disorder (e.g., anxiety, depression, substance use).

2b. Patient/client and clinical characteristics including 

type, time since, and duration of trauma exposure; 

gender; race/ethnicity; age; clinical condition; or disorder, (e.g., anxiety, depression, ADHD, conduct disorder, substance use). 

Intervention .......................... TIC models/components of care (e.g., education and 

training of providers about trauma, screening patients/clients for trauma exposure using ACEs or 

other tools, screening for symptoms, delivering pointof-care interventions, referring patients/clients for various forms of additional assessment and treatment 

for indicated needs).

TIC models/components of care (e.g., education and 

training of providers about trauma, screening patients/clients for trauma exposure using ACEs or 

other tools, screening for symptoms, delivering point 

of care interventions, referring patients/clients for various forms of additional assessment and treatment 

for indicated needs). 

1a. single or multi-component, individual or group, targeting organizations, providers, patients/clients, caregivers, or a combination, training, screening.2a. single or multi-component, individual or group, targeting organizations, providers, patients/clients, caregivers, or a combination, training, screening. 

Comparator .......................... No TIC model of care/usual or routine care (CAU) ........ No TIC model of care/usual or routine care (CAU). 

Other TIC model or component(s) of care, evidencebased therapies for trauma-related conditions (e.g., 

prolonged exposure, cognitive processing therapy) or 

approaches (e.g., Collaborative Care).

Other TIC model or component(s) of care, evidencebased therapies for trauma-related conditions (e.g., 

trauma-focused CBT) or approaches (e.g., Collaborative Care). 

Outcome ............................... Trauma-Specific: Additional or repeat trauma exposure 

from the point-of-care in the course of care/service 

delivery (e.g., retraumatization).

Trauma-Specific: Additional or repeat trauma exposure 

from the point-of-care in the course of care/service 

delivery (e.g., retraumatization). 

Process outcomes: Health care outcomes/utilization/referral, provider burnout/mental health.Process outcomes: Healthcare outcomes/utilization/referral, provider outcomes burnout/mental health. 

Organizational/practice/systems outcomes: Intake and 

referral processes (e.g., wait times), disseminated 

policies, trainings, staffing (e.g., scribes), administrative requirements, access to treatment, workforce diversity.

Organizational/practice/systems outcomes: Intake and 

referral processes (e.g., wait times), disseminated 

policies, trainings, staffing (e.g., scribes), administrative requirements, access to treatment, workforce diversity, anti-racism principles. 

Patient/client-centered outcomes: Physical and mental 

health outcomes, functioning, clinical improvement, 

patient/client engagement, trust, comfort or satisfaction, and strengths-based outcomes (e.g., quality of 

life).

Patient/client-centered outcomes: Physical and mental 

health outcomes, functioning, clinical improvement, 

patient/client engagement, trust, comfort or satisfaction, and strengths-based outcomes (e.g., quality of 

life). 

Harms: Includes displacement of evidence based care 

(e.g., screening for anxiety, depression, substance 

use, suicide risk), increase in patient/client aggression or other behavioral misconduct.

Harms: Includes displacement of evidence based care 

(e.g., screening for developmental milestones, 

ADHD, depression, anxiety, suicide risk, substance 

use), increase in patient/client aggression or other 

behavioral misconduct. 

Timing .................................. Any .................................................................................. Any. 

Setting .................................. Routine or emergency healthcare in any setting that 

provides human or social services, including in nontraditional settings (e.g., HIV clinics providing behavioral health care).

Routine or emergency healthcare in any setting that 

provides human or social services, including in nontraditional settings (e.g., school-based clinics providing behavioral health care). 

Dated: October 27, 2023. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2023–24214 Filed 11–1–23; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)– 

TS24–010, Identify and Evaluate 

Potential Risk Factors for Amyotrophic 

Lateral Sclerosis (ALS). 

Date: April 9, 2024. 

Time: 8:30 a.m.–5 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Mikel L. Walters, Ph.D., Scientific 

Review Officer, National Center for 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 88, No. 211 / Thursday, November 2, 2023 / Notices 75287 

Injury Prevention and Control, Centers 

for Disease Control and Prevention, 

4770 Buford Highway NE, Mailstop 

S106–9, Atlanta, Georgia 30341. 

Telephone: (404) 639–0913; Email: 

MWalters@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–24242 Filed 11–1–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)– 

CE24–030, Research Grants for 

Preventing Violence and Violence 

Related Injury (R01). 

Dates: April 2–3, 2024. 

Times: 8:30 a.m.–5 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Carlisha Gentles, Pharm.D., B.C.P.S., 

C.D.C.E.S., Scientific Review Officer, 

National Center for Injury Prevention 

and Control, Centers for Disease Control 

and Prevention, 4770 Buford Highway 

NE, Mailstop F–63, Atlanta, Georgia 

30341. Telephone: (770) 488–1504; 

Email: CGentles@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–24241 Filed 11–1–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)– 

CE22–003, Rigorously Evaluating 

Programs and Policies to Prevent Child 

Sexual Abuse (CSA). 

Date: April 11, 2024. 

Time: 8:30 a.m.–5 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Mikel L. Walters, Ph.D., Scientific 

Review Officer, National Center for 

Injury Prevention and Control, Centers 

for Disease and Prevention, 4770 Buford 

Highway NE, Mailstop S106–9, Atlanta, 

Georgia 30341. Telephone: (404) 639– 

0913; Email: MWalters@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–24239 Filed 11–1–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)– 

CE24–012, Rigorous Evaluation of 

Policy-Level Interventions to Prevent 

Overdose. 

Date: March 26, 2024. 

Time: 8:30 a.m.–5 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Aisha L. Wilkes, M.P.H., Scientific 

Review Officer, National Center for 

Injury Prevention and Control, Centers 

for Disease Control and Prevention, 

4770 Buford Highway NE, Mailstop 

S106–9, Atlanta, Georgia 30341. 

Telephone (404) 639–6473; Email: 

AWilkes@cdc.gov. 


khammond on DSKJM1Z7X2PROD with NOTICES